Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how weโre using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: https://t.co/9pDyBXaAqT
Today, MSD completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on scienceโdriven innovation. Learn more: https://t.co/7EzLFGZsUb
Weโre proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation.
This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients.
Learn more about the landmark partnership: https://t.co/2Z4N1yYFbT
Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: https://t.co/mRFXAI5awI #ophthalmology
Today, we announced an agreement to acquire Terns Pharmaceuticals, adding a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML) to our growing #hematology pipeline: https://t.co/WlX50ZK8bC
@RastogiSonsy@Merck Hi, it looks like your post may have intended to tag another company. Please note our company is Merck in the US and Canada and @MSDInvents elsewhere.
Today, we announced the completion of the acquisition of Cidara Therapeutics, diversifying our pipeline with a novel late-phase antiviral candidate being evaluated for the prevention of symptomatic influenza in certain individuals at high risk of complications. Learn More. https://t.co/JWRKoFIjSG
Today, we signed a most favored nations agreement with the Trump administration. Addressing global pricing imbalances through a fair, value-based approach is essential, and this agreement helps us do that responsibly, while improving access for U.S. patients at an affordable price. A key component of this agreement is ensuring access to our investigational oral PCSK9 inhibitor being evaluated in patients with elevated cholesterol. Once approved, this medicineย will be available through a direct-to-patient program making it easier to get at affordable prices. Over time we hope to be able to broaden access to this important medicine globally at affordable prices. https://t.co/qLh0z0Xk33
Weโre excited to share new data from our neuroscience pipeline at CTAD 2025, including results for two #AlzheimersDisease candidates. The U.S. FDA has granted Fast Track Designation to one of our candidates for the treatment of Alzheimer's. Learn more: https://t.co/9dOP8SpofG
Today, we announced an agreement to acquire Cidara Therapeutics, Inc., diversifying our respiratory portfolio to include an investigational long-acting strain-agnostic antiviral agent. https://t.co/a706symZNM
Today, we announced a strategic funding agreement with Blackstone, positioning our company to advance development of an investigational antibody-drug conjugate targeting TROP2 while we continue to advance our broad and expansive pipeline. Read more: https://t.co/WnEnjf2Rj9
@Milenio@Merck Hi, it looks like your post may have intended to tag another company. Please note our company is @Merck in US and Canada and @MSDInvents outside US and Canada.